NASH Drugs
Oct 18, 2024
From NASH to MASH: Unraveling the Evolution and Future of Liver Disease Treatment
In the ever-evolving world of liver disease, the shift from Nonalcoholic Steatohepatitis (NASH) to Metabolic Associated Steatotic Hepatitis (MASH) marks a revolutionary leap in our understanding and approach to treatment. This transition isn't merely a rebranding; it signifies a profound recognition of the intricat...
Read More...
Oct 14, 2024
6 Promising Late-stage NASH Drugs to Challenge REZDIFFRA’s Supremacy
At present, REZDIFFRA stands as the only approved NASH drug to battle the devastating disease. This once-daily, oral THR-β agonist received a fast-track nod from the US FDA in March 2024, thanks to the impressive outcomes of the Phase III MAESTRO-NASH trial. But with one trailblazer already in the ring, the race is...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
